Antibodies in the study of multiple drug resistance.
Multidrug resistance (MDR) is a major problem in cancer chemotherapy. As P-glycoprotein is the key molecule in MDR, many investigators have constructed anti-P-glycoprotein monoclonal antibodies (MAbs). Those antibodies, including MRK16 and C219, were used for elucidation of the mechanism of MDR and for overcoming of MDR. This article describes the characterization of the antibodies against the P-glycoprotein and other proteins of multidrug-resistant tumor cells, and discusses the therapeutic implication of the antibodies.
Heike
Y
Y
Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
Tsuruo
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000633:toxicity; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004351:Drug Resistance / Q000276:immunology / Q000502:physiology*; D006023:Glycoproteins / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008807:Mice, Inbred BALB C / Q000276:immunology; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006023:Glycoproteins